A Case of Primary Refractory Immune Thrombocytopenia: Challenges in Choice of Therapies

The value of combination therapy for refractory ITP is not well defined. We present the case of a 29-year-old male with severe ITP refractory to initial standard therapy including steroids, IVIG, and subsequent splenectomy, who was treated with the combination therapy of rituximab, romiplostim, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hanyin, Tuncer, Hande
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6051095/
https://www.ncbi.nlm.nih.gov/pubmed/30057832
http://dx.doi.org/10.1155/2018/8207017
_version_ 1783340454586089472
author Wang, Hanyin
Tuncer, Hande
author_facet Wang, Hanyin
Tuncer, Hande
author_sort Wang, Hanyin
collection PubMed
description The value of combination therapy for refractory ITP is not well defined. We present the case of a 29-year-old male with severe ITP refractory to initial standard therapy including steroids, IVIG, and subsequent splenectomy, who was treated with the combination therapy of rituximab, romiplostim, and mycophenolate and eventually developed thrombocytosis requiring plateletpheresis. Our case highlights the importance of the need to understand predictors of response to standard upfront treatment of acute ITP.
format Online
Article
Text
id pubmed-6051095
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-60510952018-07-29 A Case of Primary Refractory Immune Thrombocytopenia: Challenges in Choice of Therapies Wang, Hanyin Tuncer, Hande Case Rep Hematol Case Report The value of combination therapy for refractory ITP is not well defined. We present the case of a 29-year-old male with severe ITP refractory to initial standard therapy including steroids, IVIG, and subsequent splenectomy, who was treated with the combination therapy of rituximab, romiplostim, and mycophenolate and eventually developed thrombocytosis requiring plateletpheresis. Our case highlights the importance of the need to understand predictors of response to standard upfront treatment of acute ITP. Hindawi 2018-07-03 /pmc/articles/PMC6051095/ /pubmed/30057832 http://dx.doi.org/10.1155/2018/8207017 Text en Copyright © 2018 Hanyin Wang and Hande Tuncer. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Wang, Hanyin
Tuncer, Hande
A Case of Primary Refractory Immune Thrombocytopenia: Challenges in Choice of Therapies
title A Case of Primary Refractory Immune Thrombocytopenia: Challenges in Choice of Therapies
title_full A Case of Primary Refractory Immune Thrombocytopenia: Challenges in Choice of Therapies
title_fullStr A Case of Primary Refractory Immune Thrombocytopenia: Challenges in Choice of Therapies
title_full_unstemmed A Case of Primary Refractory Immune Thrombocytopenia: Challenges in Choice of Therapies
title_short A Case of Primary Refractory Immune Thrombocytopenia: Challenges in Choice of Therapies
title_sort case of primary refractory immune thrombocytopenia: challenges in choice of therapies
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6051095/
https://www.ncbi.nlm.nih.gov/pubmed/30057832
http://dx.doi.org/10.1155/2018/8207017
work_keys_str_mv AT wanghanyin acaseofprimaryrefractoryimmunethrombocytopeniachallengesinchoiceoftherapies
AT tuncerhande acaseofprimaryrefractoryimmunethrombocytopeniachallengesinchoiceoftherapies
AT wanghanyin caseofprimaryrefractoryimmunethrombocytopeniachallengesinchoiceoftherapies
AT tuncerhande caseofprimaryrefractoryimmunethrombocytopeniachallengesinchoiceoftherapies

Ejemplares similares